Cargando…

Long-term effects of immunotherapy with a brain penetrating Aβ antibody in a mouse model of Alzheimer’s disease

BACKGROUND: Brain-directed immunotherapy is a promising strategy to target amyloid-β (Aβ) deposits in Alzheimer’s disease (AD). In the present study, we compared the therapeutic efficacy of the Aβ protofibril targeting antibody RmAb158 with its bispecific variant RmAb158-scFv8D3, which enters the br...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gustavsson, Tobias, Metzendorf, Nicole G., Wik, Elin, Roshanbin, Sahar, Julku, Ulrika, Chourlia, Aikaterini, Nilsson, Per, Andersson, Ken G., Laudon, Hanna, Hultqvist, Greta, Syvänen, Stina, Sehlin, Dag
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10152635/ https://www.ncbi.nlm.nih.gov/pubmed/37131196 http://dx.doi.org/10.1186/s13195-023-01236-3

Ejemplares similares

Brain pharmacokinetics of mono- and bispecific amyloid-β antibodies in wild-type and Alzheimer’s disease mice measured by high cut-off microdialysis
por: Julku, Ulrika, et al.
Publicado: (2022)

Reduction of αSYN Pathology in a Mouse Model of PD Using a Brain-Penetrating Bispecific Antibody
por: Roshanbin, Sahar, et al.
Publicado: (2022)

Efficient clearance of Aβ protofibrils in AβPP-transgenic mice treated with a brain-penetrating bifunctional antibody
por: Syvänen, Stina, et al.
Publicado: (2018)

Blood–brain barrier penetrating neprilysin degrades monomeric amyloid-beta in a mouse model of Alzheimer’s disease
por: Rofo, Fadi, et al.
Publicado: (2022)

PET Imaging in Preclinical Anti-Aβ Drug Development
por: Syvänen, Stina, et al.
Publicado: (2022)

Enhanced neprilysin-mediated degradation of hippocampal Aβ42 with a somatostatin peptide that enters the brain
por: Rofo, Fadi, et al.
Publicado: (2021)

Antibody-Based In Vivo PET Imaging Detects Amyloid-β Reduction in Alzheimer Transgenic Mice After BACE-1 Inhibition
por: Meier, Silvio R., et al.
Publicado: (2018)

Wide-Ranging Effects on the Brain Proteome in a Transgenic Mouse Model of Alzheimer’s Disease Following Treatment with a Brain-Targeting Somatostatin Peptide
por: Rofo, Fadi, et al.
Publicado: (2021)

SPECT imaging of distribution and retention of a brain-penetrating bispecific amyloid-β antibody in a mouse model of Alzheimer’s disease
por: Gustavsson, Tobias, et al.
Publicado: (2020)

Development of brain-penetrable antibody radioligands for in vivo PET imaging of amyloid-β and tau
por: Banka, Vinay, et al.
Publicado: (2023)

Pinpointing Brain TREM2 Levels in Two Mouse Models of Alzheimer’s Disease
por: Meier, Silvio R., et al.
Publicado: (2021)

A Brain-Targeting Bispecific-Multivalent Antibody Clears Soluble Amyloid-Beta Aggregates in Alzheimer’s Disease Mice
por: Rofo, Fadi, et al.
Publicado: (2022)

Bivalent Brain Shuttle Increases Antibody Uptake by Monovalent Binding to the Transferrin Receptor
por: Hultqvist, Greta, et al.
Publicado: (2017)

Efficient and inexpensive transient expression of multispecific multivalent antibodies in Expi293 cells
por: Fang, Xiaotian T., et al.
Publicado: (2017)

ImmunoPET imaging of amyloid-beta in a rat model of Alzheimer’s disease with a bispecific, brain-penetrating fusion protein
por: Bonvicini, Gillian, et al.
Publicado: (2022)

Brain pharmacokinetics of two BBB penetrating bispecific antibodies of different size
por: Faresjö, Rebecca, et al.
Publicado: (2021)

Engineered antibodies: new possibilities for brain PET?
por: Sehlin, Dag, et al.
Publicado: (2019)

(11)C-PiB and (124)I-Antibody PET Provide Differing Estimates of Brain Amyloid-β After Therapeutic Intervention
por: Meier, Silvio R., et al.
Publicado: (2022)

Age, dose, and binding to TfR on blood cells influence brain delivery of a TfR-transported antibody
por: Faresjö, Rebecca, et al.
Publicado: (2023)

Novel multivalent design of a monoclonal antibody improves binding strength to soluble aggregates of amyloid beta
por: Rofo, Fadi, et al.
Publicado: (2021)

Functionalization of Radiolabeled Antibodies to Enhance Peripheral Clearance for High Contrast Brain Imaging
por: Schlein, Eva, et al.
Publicado: (2022)

Transferrin Receptor Binding BBB-Shuttle Facilitates Brain Delivery of Anti-Aβ-Affibodies
por: Faresjö, Rebecca, et al.
Publicado: (2022)

Standardized Preclinical In Vitro Blood–Brain Barrier Mouse Assay Validates Endocytosis-Dependent Antibody Transcytosis Using Transferrin-Receptor-Mediated Pathways
por: Morrison, Jamie I., et al.
Publicado: (2023)

Pharmacokinetics, biodistribution and brain retention of a bispecific antibody-based PET radioligand for imaging of amyloid-β
por: Sehlin, Dag, et al.
Publicado: (2017)

Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer's disease
por: Sehlin, Dag, et al.
Publicado: (2016)

Long-Term Effects of Traumatic Brain Injury in a Mouse Model of Alzheimer’s Disease
por: Zyśk, Marlena, et al.
Publicado: (2019)

Introducing or removing heparan sulfate binding sites does not alter brain uptake of the blood–brain barrier shuttle scFv8D3
por: de la Rosa, Andrés, et al.
Publicado: (2022)

Fluorine-18-Labeled Antibody Ligands for PET Imaging of Amyloid-β in Brain
por: Syvänen, Stina, et al.
Publicado: (2020)

Delineating Amyloid Plaque Associated Neuronal Sphingolipids in Transgenic Alzheimer’s Disease Mice (tgArcSwe) Using MALDI Imaging Mass Spectrometry
por: Kaya, Ibrahim, et al.
Publicado: (2016)

Pyroglutamation of amyloid-βx-42 (Aβx-42) followed by Aβ1–40 deposition underlies plaque polymorphism in progressing Alzheimer's disease pathology
por: Michno, Wojciech, et al.
Publicado: (2019)

Cryo-EM of Aβ fibrils from mouse models find tg-APP(ArcSwe) fibrils resemble those found in patients with sporadic Alzheimer’s disease
por: Zielinski, Mara, et al.
Publicado: (2023)

Pretargeted Imaging beyond the Blood–Brain Barrier—Utopia or Feasible?
por: Lopes van den Broek, Sara, et al.
Publicado: (2022)

Development of the First Tritiated Tetrazine: Facilitating Tritiation of Proteins
por: Radjani Bidesi, Natasha Shalina, et al.
Publicado: (2022)

Removal of prolyl oligopeptidase reduces alpha-synuclein toxicity in cells and in vivo
por: Svarcbahs, Reinis, et al.
Publicado: (2018)

Behavioural and dopaminergic changes in double mutated human A30P*A53T alpha-synuclein transgenic mouse model of Parkinson´s disease
por: Kilpeläinen, Tommi, et al.
Publicado: (2019)

Prolyl Oligopeptidase Regulates Dopamine Transporter Oligomerization and Phosphorylation in a PKC- and ERK-Independent Manner
por: Julku, Ulrika H., et al.
Publicado: (2021)

Single-cell RNAseq and longitudinal proteomic analysis of a novel semi-spontaneous urothelial cancer model reveals tumor cell heterogeneity and pretumoral urine protein alterations
por: Kerzeli, Iliana K., et al.
Publicado: (2021)

Structure and dynamics conspire in the evolution of affinity between intrinsically disordered proteins
por: Jemth, Per, et al.
Publicado: (2018)

DNA methylation and histone modifications regulate SOX11 expression in lymphoid and solid cancer cells
por: Nordström, Lena, et al.
Publicado: (2015)

Cancer incidence in female laboratory employees: extended follow-up of a Swedish cohort study
por: Gustavsson, Per, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_g2k0ku432llpaa1d4vfpf0t85j